A Study on the factors associated with continuing treatment with brexpiprazole in patients with schizophrenia using MENTAT

A Study on the factors associated with continuing treatment with brexpiprazole in patients with schizophrenia using MENTAT - A Study on the factors associated with continuing treatment with brexpiprazole in patients with schizophrenia using MENTAT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045075

Enrollment

400

Registered

2021-08-20

Start date

2021-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who started treatment with brexpiprazole for schizophrenia within the enrollment period (April 18, 2018 to March 31, 2020) (Index date is defined as the earliest date of prescription at the time of diagnosis of schizophrenia within the enrollment period) 2)Patients aged 18 years or older on the index date

Exclusion criteria

Exclusion criteria: 1) Patients with mood [affective] disorder, dementia, disorders of psychological development, or hyperactivity disorder at the time of Index date 2) Patients who have been treated with brexpiprazole less than 1 mg / day and more than 2 mg / day even once

Design outcomes

Primary

Measure	Time frame
To exploratively study the factors affecting the continuing treatment duration in patients with schizophrenia who started treatment with brexpiprazole	—

Secondary

Measure	Time frame
Treatment continuation rates with brexpiprazole	—

Countries

Japan

Contacts

Public ContactHisashi Akiyoshi

Otsuka Pharmaceutical Co., Ltd. Medical Affairs Department

akiyoshih@otsuka.jp03-6717-1400

Outcome results